Cristalia Produtos Quimicos Farmaceuticos Ltda.

Cristalia Productos Quimicos Farmaceuticos Ltda.

Fundacao De Amparoa Pesquisa Do Estado De Sao Paulo-fapesp

Ogari Pacheco

Valter Russo

Maria Alice Böckelmann

Elisa Russo

Edson Luiz Lima

José Antônio Martins

Antonio Carlos Teixeira

Vincenzo De Sio

Maria Alice Bockelmann

Simone Rosatto

Marcelo Secatto

Wellington Camarotto

Marcelo Da Silva

Elisa Rusoo

Murilo Massoni

Lucildes Mercure

Osvaldo Augusto Sant'Anna

Jivaldo Matos

Leandro Camargo

Márcia Fantini

Lucildes Mercuri

The present invention refers to an industrial process and system that is efficient and advantageous for inactivation of liquid wastes contaminated by mutagenic, genotoxic and/or teratogenic substances arising from high potency APIs production using inactivation chemical agents and excluding ozone, heat or UV light source.

Industrial process and system for the inactivation of liquid waste

The present invention relates to an efficient and industrially advantageous process for preparing temozolomide and the carbamoyl-AICA intermediate through the use of N-methyl carbamoylimidazole in a good overall yield and high purity.

Process for preparing temozolomide and an intermediary

The present invention relates to a product named 'immunogenical complex', which comprises an adjuvant characterized by solid particles of highly ordinated nanostructured mesoporous silica, preferably, SBA-15 Silica, and vaccinal antigens of several natures, encapsulated in the referred to adjuvants. The immunogenical complex of the present invention allows the presentation of the antigens that compose it to lymphocytes, in a safe, gradual and extended way, which leads to a more efficient immunological memory, increases the immunogenicity of the antigen and improves the production of antibodies. This ensures an efficient immunological protection with fewer amounts of antigens and/or less repetitions of vaccinal doses. In addition, the characteristics of the immunogenical complex of the present invention promotes effective immunity induction, homogeneous in 'god and bad respondent' individuals.

Immunogenical complex formed by vaccinal antigens encapsulated by nanostructured mesoporous silica

The present invention refers to a process for the preparation of fluoromethyl 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether (sevoflurane) which includes a step that consists of reacting hexafluoroisopropanol with a formaldehyde equivalent selected among paraformaldehyde or 1,3,5-trioxane, a chlorinating agent selected from the group consisting of oxalyl chloride, phosphorus trichloride, phosphorus pentachloride, phosphorus oxychloride, sulfuryl chloride and thionyl chloride, and a strong acid selected from the group consisting of concentrated or fuming sulfuric acid resulting in the formation of the intermediate sevochlorane which is converted to sevoflurane in a second step which consists of reacting sevochlorane with an alkali metal fluoride, or a linear or branched chain tetra-alkyl quarternary ammonium fluoride in the presence of a sub-stoichiometric quantity of an alkali metal iodide, or a linear or branched alkyl chain tetra-alkyl quarternary ammonium iodide, preferably in a solvent.

Process for the preparation of fluoromethyl 2,2,2-trifluoro-1-(trifluoromethyl) ethyl ether

The present invention refers to a process for the preparation of chloromethyl 2,2,2-trifluoro-1-(trifluoromethyl) ethyl ether (sevochlorane), which consists of reacting hexafluoroisopropanol with: a formaldehyde equivalent selected between paraformaldehyde or 1,3,5-trioxane, a chlorinating agent selected from the group consisting of oxalyl chloride, phosphorus trichloride, phosphorus pentachloride, phosphorus oxychloride, sulfuryl chloride and thionyl chloride, and a strong acid selected from the group consisting of concentrated or fuming sulfuric acid. Said process provides sevochlorane in high purity and yield, which can be converted to sevoflurane by known means.

Process for the preparation of chloromethyl 2,2,2-trifluoro-1-(trifluoromethyl) ethyl ether

The present invention has as objective the stabilization of a fluoroether compound against degradation by acid substances. The stabilizers proposed are selected among propylene glycol, polyethylene glycol, hexylene glycol, 1,3-butylene glycol and a saturated cyclic alcohol preferably menthol and are used for preparing stable pharmaceutical compositions of a fluoroether compound. Method for stabilizing a fluoroether compound and use of stabilizers agents for precluding the degradation of a fluoroether are also described.

Stable pharmaceutical composition of fluoroether compound for anesthetic use method for stabilizing a fluoroether compound, use of stabilizer agent for precluding the degradation of a fluoroether compound

The present invention describes ternary and quaternary eutectic mixtures composed by active local anesthetic substances. These eutectic mixtures possess melting point inferior to 20&#xb0; C. and consist of homogeneous liquid useful in the preparation o pharmaceutical compositions for topical anesthesia or analgesia of tissues as skin or mucous.

Ternary and quaternary eutectic mixtures of local anesthetics substances

The present invention describes a soluble stable pharmaceutical composition for the administration of HIV protease inhibitors. More specifically the composition comprises a solution of an HIV protease inhibitor in a combination of suitable pharmaceutical organic solvents, a surfactant and a bioavailability enhancer. It is also described a process for the obtainment of concentrated pharmaceutical compositions used in the administration of HIV protease inhibitors compounds. The composition of the present invention is suitable for the preparation of oral solutions for the administration of active drugs and for the encapsulation in hard gelatin capsules or soft gelatin capsules.

Soluble, stable and concentrated pharmaceutical composition compromising ritonavir and process for preparing thereof

Growing community of inventors

Itapira, Brazil

Ogari Pacheco